Royalty Cash Per Share from 2010 to 2025

RPRX Stock  USD 30.75  0.20  0.65%   
Royalty Pharma Cash Per Share yearly trend continues to be fairly stable with very little volatility. Cash Per Share will likely drop to 0.95 in 2025. During the period from 2010 to 2025, Royalty Pharma Cash Per Share regression line of annual values had r-squared of  0.0005 and arithmetic mean of  3.33. View All Fundamentals
 
Cash Per Share  
First Reported
2010-12-31
Previous Quarter
1
Current Value
0.95
Quarterly Volatility
1.85603688
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Royalty Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Royalty Pharma's main balance sheet or income statement drivers, such as Interest Expense of 226 M, Total Revenue of 2.8 B or Research Development of 57.5 M, as well as many indicators such as Price To Sales Ratio of 10.69, Dividend Yield of 0.0361 or PTB Ratio of 3.83. Royalty financial statements analysis is a perfect complement when working with Royalty Pharma Valuation or Volatility modules.
  
Check out the analysis of Royalty Pharma Correlation against competitors.

Latest Royalty Pharma's Cash Per Share Growth Pattern

Below is the plot of the Cash Per Share of Royalty Pharma Plc over the last few years. It is Royalty Pharma's Cash Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Royalty Pharma's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 3.34 X10 Years Trend
Very volatile
   Cash Per Share   
       Timeline  

Royalty Cash Per Share Regression Statistics

Arithmetic Mean3.33
Geometric Mean2.83
Coefficient Of Variation55.78
Mean Deviation1.45
Median2.83
Standard Deviation1.86
Sample Variance3.44
Range5.8082
R-Value(0.02)
Mean Square Error3.69
R-Squared0.0005
Significance0.94
Slope(0.01)
Total Sum of Squares51.67

Royalty Cash Per Share History

2025 0.95
2024 1.0
2023 1.11
2022 5.54
2021 6.76
2020 5.31
2019 2.17

About Royalty Pharma Financial Statements

Royalty Pharma investors use historical fundamental indicators, such as Royalty Pharma's Cash Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Royalty Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cash Per Share 1.00  0.95 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Royalty Stock Analysis

When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.